AI-generated summary
The authors report a before and after pilot study of transvaginal photobiomodulation in 13 women with chronic pelvic pain who completed nine treatments, with 10 followed to six months. Pain scores on the Short Form-McGill Pain Questionnaire fell from a mean of 19.7 at baseline to lower values at one week, three months and six months, which the authors describe as significant and sustained. Without a control group, these results are preliminary and need controlled confirmation.
- Participants
- 13
- Who or what was studied
- Women with chronic pelvic pain
- Limits stated in the abstract
- The study was an uncontrolled, observational pilot with a small sample, and only 10 of 13 women were followed to six months.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Chronic pelvic pain (CPP) is a common and debilitating condition that affects millions of U.S. women. Most treatments are ineffective and innovative new therapies are desperately needed. Large, controlled studies show that photobiomodulation (PBM) can reduce pain in patients with other chronic pain conditions, such as low back pain, neck pain, and fibromyalgia. The objective of this pilot study was to determine if transvaginal PBM (TV-PBM) can reduce pain in women with CPP.
Methods
We conducted a before and after, observational, pilot study. Patients completed the Short Form-McGill Pain Questionnaire (SF-MPQ) at baseline, 1 week, 3 months, and 6 months after nine treatments of TV-PBM. Clinicians completed the Clinical Global Impression Scale (CGI) assessing patient illness severity at the same time. Wilcoxon rank-sum t-tests and effect size using Cohen's d coefficient (low effect size if d < 0.2, medium if 0.2 < d > 8, and high if d > 0.8) was used to measure degree of pain improvement, which was also considered clinically significant if pain reduction was >30%.
Results
Thirteen women completed 9 treatments, and 10 women were successfully followed to 6 months. At baseline, the mean SF-MPQ score was 19.7 (standard deviation [SD] ± 5.9). Compared with baseline, 60% improved; the mean SF-MPQ score decreased to 10.0 (SD ±7.5, p = 0.004, d = 1.6) at 1 week after treatment, to 9.7 (SD ±7.9, p = 0.005, d = 1.7) at 3 months, and 8.2 (SD ±8.1, p = 0.002, d = 1.9) at 6 months.
Conclusion
Transvaginal PBM provided significant and sustained pain relief to women with CPP up to 6 months. Further controlled studies are needed to confirm these findings, however, in this initial pilot, TV-PBM shows promise.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Pilot study, Effect size, Fibromyalgia. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.